A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma
- 35 Downloads
Background Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Methods The effects of thiostrepton on the proliferation, migration, and invasion of NPC cells were investigated by a WST-1 assay, wound healing assay, and cell invasion assay, respectively. Microarrays were conducted and further analyzed by Ingenuity Pathways Analysis (IPA) to determine the molecular mechanism by which thiostrepton affects NPC cells. Results Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. The microarray data analyzed by IPA indicated the top 5 ingenuity canonical pathways, which were unfolded protein response, NRF2-mediated oxidative stress response, retinoate biosynthesis I, choline biosynthesis III, and pancreatic adenocarcinoma signaling. Conclusion Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.
KeywordsNasopharyngeal carcinoma Thiostrepton Anticancer drug Microarray
The authors thank Clinical Research Core Laboratory at Taipei Veterans General Hospital for the facility support.
This research was supported by grants from the Taipei Veterans General Hospital (V105-B–022 and V108C-088), and Ministry of Science and Technology, Taiwan (MOST 106–2314-B-075-035-MY3 and MOST 107–2320-B-010-040-MY3).
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals.
- 5.Lan MY, Yang WL, Lin KT, Lin JC, Shann YJ, Ho CY, Huang CY (2014) Using computational strategies to predict potential drugs for nasopharyngeal carcinoma. Head Neck 36:1398–1407Google Scholar
- 8.NCATS Inxight: Drugs (2018) THIOSTREPTON HR4S203Y18. https://drugs.ncats.io/drug/HR4S203Y18. Accessed 26 Mar 2019
- 16.Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY (2015) FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 6:2349–2365Google Scholar
- 17.Jiang L, Wang P, Chen L, Chen H (2014) Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol 7:5450–5460Google Scholar
- 22.Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM, Chuang SM (1990) Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Investig 62:713–724Google Scholar
- 23.Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM, Chuang SM, Wang CC (1993) Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Investig 68:716–727Google Scholar
- 24.Katoh M, Katoh M (2004) Human FOX gene family (review). Int J Oncol 25:1495–1500Google Scholar
- 28.Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18:830–850CrossRefGoogle Scholar
- 38.Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH, Wan H, Waseem A, Parkinson EK, Fortune F, Teh MT (2009) FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 4:e4849CrossRefGoogle Scholar
- 47.Jang HJ, Hong EM, Kim M, Kim JH, Jang J, Park SW, Byun HW, Koh DH, Choi MH, Kae SH, Lee J (2016) Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Oncotarget 7:46219–46229Google Scholar
- 48.Han L, Jiang J, Ma Q, Wu Z, Wang Z (2018) The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway. Int J Oncol 52:2101–2109Google Scholar
- 50.Yin J, Liu H, Liu Z, Owzar K, Han Y, Su L, Wei Y, Hung RJ, Brhane Y, McLaughlin J, Brennan P, Bickeboeller H, Rosenberger A, Houlston RS, Caporaso N, Landi MT, Heinrich J, Risch A, Christiani DC, Amos CI, Wei Q (2017) Pathway-analysis of published genome-wide association studies of lung cancer: a potential role for the CYP4F3 locus. Mol Carcinog 56:1663–1672CrossRefGoogle Scholar
- 52.Zhou S, Shen Y, Zheng M, Wang L, Che R, Hu W, Li P (2017) DNA methylation of METTL7A gene body regulates its transcriptional level in thyroid cancer. Oncotarget 8:34652–34660Google Scholar